The Moroccan scientist, Moncef Selawi, who obtained a doctorate in immunology, also holds Belgian and American citizenship.
Al-Salawi said, at a press conference in the White House garden, that he viewed this appointment as an honor and opportunity to provide service to the United States and the world, in light of the pandemic that affected more than four and a half million.
He said he had seen early data, expecting to have hundreds of millions of doses of vaccine by the end of 2020.
Biography of Salawi:
He holds a Ph.D. in Molecular Biology.
He has held several courses at prestigious American universities such as Harvard Medical School and Tufts University.
He was a professor at the University of Mons, Belgium, and wrote nearly a hundred papers.
He spent thirty years working for the giant "GlaxoSmithKline", a British global firm.
In 2006, he was appointed to head the Research and Development division of GlaxoSmithKline.
He announced a plan to create a group specialized in neuroscience in Shanghai, China.
Bet on hiring nearly a thousand employees in a project costing $ 100 million, and the initiative was stopped in 2017.
In 2008, Al-Salawi supervised the acquisition by Spirit Pharmaceuticals of a UK and international pharmaceutical company in a deal valued at $ 720 million.
He oversaw the purchase of the Human Genomics Company for $ 3 billion.
Supervised the development of several vaccines; Such as the Cervarix vaccine for cervical cancer prevention, the Rotarix vaccine to protect children from viral gastroenteritis, and the Ebola epidemic vaccine.
He spent 27 years researching the Cervarix vaccine to prevent malaria until it was approved by the European Medicines Agency in 2015, the first of its kind in the world.
From Agadir to Europe:
Moncef Slaoui was born in 1959 in the city of Agadir, bordering the Atlantic Ocean in Morocco. He studied in the Kingdom of Morocco until he obtained a baccalaureate (high school) certificate from Mohamed V Secondary School in Dar Al-Baida, and then he traveled to France to study medicine when he was seventeen years old, similar to several Moroccan students who choose to complete their studies abroad.
But Al-Salawi was disappointed with me first, and he could not register himself at the French University, because the registration deadline had expired, and therefore, he decided to move towards neighboring Belgium, which is also the country of Francophone, then he studied at the Free University of Brussels and obtained a degree of "leave" in Biology.
The researcher was forced to resign from the "Moderna" company specialized in pharmacy, in order to avoid falling into a "conflict of interest", given his work at that time in a federal initiative, and it is difficult to remain an employee of a private company.